Deciphera Pharmaceuticals, Inc. (DCPH) stock soared 3.74% in the pre-market trading session at the price of $9.52 after announcing top-line results from the INTRIGUE phase-III clinical study. DCPH is a biopharmaceutical firm that discovers, develops, and commercializes new drugs to improve the lives of cancer patients.
DCPH Top-Line Results from INTRIGUE Phase-III Study
On 5th November 2021, DCPH published top-line results from the INTRIGUE Phase-III study of QINLOCK to treat patients with gastrointestinal stromal tumors. The clinical study did not satisfy the primary endpoint of advanced progression-free survival compared with sunitinib. INTRIGUE clinical study is a randomized, open-label, and multicenter study to evaluate the safety and efficiency of QINLOCK in patients dealing with GIST. This study evaluated over 453 patients for four weeks by dosing with either 150 mg of QINLOCK or 50 mg of sunitinib once every day.
Management Comments
Chief Executive Officer of DCPH, Steve Hoerter, remarked that they are disappointed with the results shown by their INTRIGUE Phase 3 study. The company will present complete results from the INTRIGUE clinical study at an upcoming conference. He thanked all the patients and the healthcare specialists who had participated in the INTRIGUE clinical study. They will ensure that all patients in the fourth-line GIST therapy setting will get access to QINLOCK, he added.
DCPH Third Quarter 2021 Financial Results
On 2nd November 2021, DCPH published its financial results for the third quarter ended 30th September 2021 and presented corporate updates.
Financial Highlights
DCPH reported total revenue of $23.2 million for the three months ended 30th September 2021. Net product revenue from sales of QINLOCK was $21.7 million, while collaboration revenue was $1.5 million for the third quarter of 2021. For the third quarter of 2021, the net loss was $79.8 million, or per share of $1.37. Net loss was $63.7 million, or per share of $1.13 for the same three months of the previous year. As of 30th September 2021, cash and cash equivalents totaled $392.2 million. The cash and cash equivalents were approximately $451.0 million on 30th June 2021.
